Yazar "Ekmen, Mehmet Onder" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • [ X ]
    Öğe
    ACUTE MYELOBLASTIC LEUKEMIA AND SQUAMOUS CELL LUNG CANCER: TWO SYNCRONE MALIGN TUMOR PRESENTATION
    (Pergamon-Elsevier Science Ltd, 2015) Karakus, Abdullah; Ekmen, Mehmet Onder; Ayyildiz, Mehmet Orhan
    [Abstract Not Available]
  • [ X ]
    Öğe
    Assessment of the underlying causes of the immune thrombocytopenia: Ten years experience
    (Pakistan Medical Assoc, 2017) Dal, Mehmet Sinan; Karakus, Abdullah; Dal, Tuba; Aydin, Berrin Balik; Hattapoglu, Elif; Ekmen, Mehmet Onder; Ulas, Turgay
    Objective: Immune thrombocytopenia (ITP) is an immune haematologic disorder causing platelet destruction mediated by anti-platelet antibodies. In this study we aimed to evaluate the clinical and laboratory variables of ITP patients in southeast of Turkey. Methods: In this retrospective study 167 ITP patients between 2005 and 2015 were evaluated. All patients were screened for immunological parameters including ANA (antinuclear antibodies), anti dsDNA (anti-double-strandedDNA), ACA(anti-cardiolipin) IgM and IgG, LA (lupus anticoagulants). All patients were screened for Helicobacter pylori, HBsAg (Hepatitis B surface antigen), anti-HCV (hepatitis C virus antibody), and anti-HIV 1/2 (HIV antibody) and brucellosis. Results: Among the patients, 50 (29.9%) patients were male, 117 (70.1%) were female. The age range of patients was 18-86 (mean 38.16+/-14). In 56 patients (33.5%) splenectomy was performed. 36 patients (21.6%) were positive for ANA, 5 (3%) were positive for anti dsDNA, 14 (8.4%) for ACA Ig G, and 14 (8.4%) patients for ACA IgM. LA was tested in 165 patients and 30 (18%) patients were positive for LA. Microbiologic evaluation was as follows: 16 patients (9.6%) were positive for HbsAg, 109 (65.3%) positive for Anti-HBs, 5 positive for anti-HCV (3%), 56 (33.5%) patients were positive for Helicobacter pylori antigen, 5 (2.9%) for Brucella and one patient was positive for anti-HIV 1/2. Conclusion: Immune thrombocytopenia patients have to be evaluated according to their demographic characteristics and laboratory results. Secondary causes of ITP were HIV, HCV, Helicobacter pylori, brucellosis, tuberculosis, and autoimmune diseases in our region. Management of ITP patients can change in different regions.
  • [ X ]
    Öğe
    Does the eltrompobag treatment safe or effective for refractory chronic immune thrombocytopenia patients?
    (E-Century Publishing Corp, 2016) Dal, Mehmet Sinan; Karakus, Abdullah; Cakar, Merih Kizil; Ulu, Bahar Uncu; Hattapoglu, Elif; Ekmen, Mehmet Onder; Ulas, Turgay
    Background: Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disorder characterized by immune-mediated platelet destruction and reduced platelet production. As the pathophysiology of the disease got clear, thrombopoietin receptor (TPO-R) agonists have been preferred in recent years, which seems to be an effective option in the treatment of resistant cases. Eltrombopag, a TPO-R agonist, is a second or third line medical treatment option for adults with chronic ITP. Objective: To determine the efficacy and safety of long-term eltrombopag treatment in treatment-refractory patients with primary ITP was the aim of this study. Materials and Methods: Retrospective data of 34 patients with refractory ITP who were treated with eltrombopag were examined. Efficacy and safety of the eltrombopag treatment was evaluated. Results: The total rate of response was 82%, and the median duration of response defined as the number of the platelets being over 50x10(9)/L was 14 (interquartile range: 7-28) days. In two patients, thrombosis was observed with no other additional risk factors due to or related to thrombosis. Conclusion: In spite of the fact that the responses to eltrombopag were satisfactory, patients need to be monitored closely for increasing platelet counts as well as thromboembolic events.
  • [ X ]
    Öğe
    Presentation and management of paroxysmal nocturnal hemoglobinuria: a single-center experience
    (Pagepress Publ, 2016) Dal, Mehmet Sinan; Karakus, Abdullah; Ekmen, Mehmet Onder; Ayyildiz, Orhan
    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder characterized by intravascular hemolysis. Real-world experience of PNH management is largely unreported. A retrospective analysis was undertaken based on medical records from six patients with PNH [two with aplastic anemia (AA)] treated at our center, Dicle University, Turkey. Diagnosis was based on granulocyte PNH clones, ranging from 93% to 66%. All patients had symptoms consistent with PNH. One patient was managed adequately with supportive measures only. Five were treated with the complement inhibitor eculizumab. Follow-up data (< 1 year) were available in four cases (the fifth had received only three infusions by final follow-up). Hemoglobin level in these four patients increased from 4.1-7.2 g/dL to 8.3-13.0 g/dL. Lactate dehydrogenase, a marker for hemolysis, decreased profoundly in the two non-AA patients, with more minor improvements in the two AA patients. Weakness and fatigue improved in all eculizumab-treated patients. Four of the five treated patients became transfusion independent, including the patient given only three infusions. In the remaining case, a patient with AA, transfusion requirement decreased, and abdominal pain and dysphagia resolved. No adverse events occurred. PNH can be successfully managed in routine practice.